logo
Rupee rises 13 paise to 85.92 against US dollar in early trade

Rupee rises 13 paise to 85.92 against US dollar in early trade

Mint5 hours ago

Mumbai, The rupee gained 13 paise to 85.92 against the US dollar in early trade on Wednesday amid hopes of an end to hostilities between Israel and Iran, and a strong opening in domestic equity markets.
However, rise in global crude oil prices which had declined for two consecutive sessions and FII outflows limited the gains for the local unit, according to forex traders.
At the interbank foreign exchange, the rupee opened at 86.00 before rising to 85.92, up 13 paise from its previous close. The local unit had logged its steepest single-day gain in nearly five years on Tuesday to end 73 paise higher at 86.05 against the greenback.
Brent crude, the global oil benchmark, rose 1.30 per cent to USD 68.01 per barrel in futures trade after US President Donald Trump brokered a ceasefire between Iran and Israel.
"Brent oil prices rose slightly after falling in the last two sessions with focus squarely on whether a US-brokered ceasefire between Israel and Iran will hold or not. The White House was also close to announcing a few more trade deals that raised the optimism for risky assets," Bhansali said.
The dollar index, which gauges the greenback's strength against a basket of six currencies, was trading up marginally by 0.06 per cent at 97.91.
"The dollar struggled to regain lost ground on Wednesday as investors who have been starved of good news latched on to the optimism of fragile truce between Iran and Israel as a reason to take more risk," Bhansali said, adding that the range of 85-87 continues for the dollar rupee pair.
Meanwhile, in the domestic equity market, Sensex jumped 426.79 points to 82,481.90 in early trade while Nifty was up 123.25 points to 25,167.60.
Foreign institutional investors offloaded equities worth ₹ 5,266.01 crore on a net basis on Tuesday, according to exchange data.
This article was generated from an automated news agency feed without modifications to text.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Next 12 months going to be a stock pickers' market; it would be tough to generate great returns:  Dipan Mehta
Next 12 months going to be a stock pickers' market; it would be tough to generate great returns:  Dipan Mehta

Time of India

time38 minutes ago

  • Time of India

Next 12 months going to be a stock pickers' market; it would be tough to generate great returns: Dipan Mehta

Live Events You Might Also Like: Bearish on software services stocks; biggest event for market is still July tariff deadline: Dipan Mehta You Might Also Like: Indian market not sneezing at every global event any more; 5 sectors to bet on now: Shiv Chanani (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel , Director,, says a few largecap Nifty companies like Bajaj Finance and Bharti Airtel can sustain 15%+ growth. Many mid and smallcap companies offer similar growth, but high valuations pose a challenge. The market is shifting, demanding granular stock picking for wealth creation after a period of broad gains, making the next 12 months the largecap space, there are hardly any companies in the Nifty which have the potential to grow at 15% plus. To that list, one can include Bajaj Finance, Bharti Airtel, and to an extent L&T. These three companies come to mind where growth rates can be 15% plus; maybe an M&M, and to an extent Eicher Motors. Within the Nifty companies, only five or six companies have the potential to grow at 15%. The rest I am not so sure the midcap space, many companies are growing at 15% plus. Look at all the defence companies. Look at some of the capital goods companies, some of the renewable energy equipment manufacturers and the power distribution companies. There are many businesses within the midcap, smallcap space which have the potential to grow at 15%. But the irony is that these businesses the PEG is more than three times, almost four if you have a company which has got reasonable corporate governance standards, high ROE, and 15% long-term growth, it is easily trading at 60 times plus trailing 12 months and at those valuations, I am not sure that you will get superlative returns. You may get returns in line with what the earnings growth is, but that is not going to move the needle too much in terms of wealth creation. It is a bit challenging at this point of time and one needs to get more and more granular and bottom next 12 months is going to really be a stock pickers' market and the entire situation will get very selective. It will be tough to generate great returns. The last four years were fantastic. Across the board, all stocks did well. Things are gradually changing as we have seen in the past two-three months, especially in the quarterly results which went by.I do not think much is going to change. At the end of the day, investors are focused on corporate earnings and the entire FY24-25 was a year of slowdown and consolidation. We saw a sharp reduction in the earnings growth of a lot of sectors, and a lot of companies. Then, we have had the RBI interest rate cut which was very surprising and positive at half percent. We had the Budget which reduced the personal taxes for a lot of individuals, so that should aid have had a good monsoon so far and government policies generally have been supportive. All investors are waiting for the corporate profits to improve in this financial year and June quarter onwards. June may be soft because I was disappointed with the advanced tax numbers by the corporate sector, but at some point of time around the busy season, post monsoon, we should see an improvement in demand, and in consumption even in capital goods and that should aid earnings growth. That is the only way this market can break its earlier highs and go to that 28,000, 29,000 Nifty we have to wait for the corporate earnings to move up. This is only as much that PE multiple expansion can take the market higher. A lot of the focus in the next six months is going to be on this revival of corporate earnings and let us see how that plays out. All the ingredients are there, the foundation is there that earnings should improve as compared to last year 24-25. But nothing is kind of cast in need to wait and watch and we need a more broad-based recovery in earnings to get much higher returns than what we have seen in the past year.

This Chinese café serves lattes infused with pork intestines and customers are loving it
This Chinese café serves lattes infused with pork intestines and customers are loving it

Hindustan Times

timean hour ago

  • Hindustan Times

This Chinese café serves lattes infused with pork intestines and customers are loving it

A café in Jiangyou, a city in China's southwestern Sichuan province, launched an unusual coffee blend made with cooked pork intestines. The drink, which has quickly caught public attention, is a latte infused with pork intestine liquid and chitterlings, as reported by the South China Morning Post. The café has seen its sales soar, quadrupling in numbers, with nearly 80 per cent of customers ordering the unusual latte.(Representational Image/Pexel) The coffee sells for 32 yuan (approximately US$4) per cup and promises a layered experience with three distinct taste levels – entrance, mid, and high. According to the café's owner, Zhang Yuchi, the higher the level, the stronger the pork intestine flavour. 'Red-braised pork intestine is a popular cuisine in Jiangyou,' Zhang explained. 'I thought of combining it with coffee to promote both my shop as well as this delicious food of our city.' Zhang further revealed that the pork intestines are sourced from a well-known local restaurant. The café then extracts the intestine liquid and carefully adds exactly six grams of it into each latte, a quantity that Zhang says was finalised after multiple rounds of testing. 'We add precisely 6 grams of intestine liquid into the coffee. It is an amount we decided on after rounds of tests. We want customers to taste the delicacy of intestines but we do not want to diminish the coffee flavour. We hope most people can accept it,' he said. Zhang described the flavour as a combination of sweet and salty, similar to 'salty cheese.' Since the drink gained traction online earlier this month, the cafe has seen its sales soar, quadrupling in numbers, with nearly 80 per cent of customers ordering the unusual latte. 'I am a fan of coffee. I saw someone recommending this type of intestine coffee, so I decided to give it a try,' a woman visiting from Chengdu told the media. Another customer, who travelled from northern China, shared her experience and said, 'Many people in northern China do not eat pork intestines. But I think they can accept this type of coffee.' The pork intestine latte has sparked a wide range of reactions on Chinese social media. Some are eager to try the drink, with one user saying, 'It is not a bad idea. I want to try it.' Others, however, are more sceptical. 'It is ridiculous. I am OK with both coffee and pork intestines. But not a combination of the two,' another comment read. This isn't the first time China's coffee culture has taken a creative turn. In Jiangxi province, a café made headlines for serving lattes mixed with fried chilli and hot pepper powder. Meanwhile, in Yunnan province, another café went viral by blending deep-fried worms into their coffee.

Lupin receives USFDA approval for Prucalopride Tablets
Lupin receives USFDA approval for Prucalopride Tablets

Business Standard

timean hour ago

  • Business Standard

Lupin receives USFDA approval for Prucalopride Tablets

Lupin has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Prucalopride Tablets, 1 mg, and 2 mg. Prucalopride Tablets are bioequivalent to Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals U.S.A. Inc. This product will be manufactured at Lupin's Goa facility in India. Prucalopride Tablets are indicated for the treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride Tablets, 1 mg, and 2 mg (RLD Motegrity) had estimated annual sales of USD 184 million in the U.S. (IQVIA MAT April 2025).

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store